Influenza A (H3) illness and viral aerosol shedding from symptomatic naturally infected and experimentally infected cases by Killingley, Ben & Enstone, Joanne
Influenza Other Respi Viruses. 2020;00:1–10.    |  1wileyonlinelibrary.com/journal/irv
 
Received: 15 May 2020  |  Revised: 8 July 2020  |  Accepted: 9 July 2020
DOI: 10.1111/irv.12790  
O R I G I N A L  A R T I C L E
Influenza A (H3) illness and viral aerosol shedding from 
symptomatic naturally infected and experimentally infected 
cases
Paul Jacob Bueno de Mesquita1  |   Jonathan Nguyen-Van-Tam2  |   Ben Killingley2 |   
Joanne Enstone2 |   Robert Lambkin-Williams3  |   Anthony S. Gilbert3 |   
Alexander Mann3 |   John Forni3 |   Jing Yan1 |   Jovan Pantelic1 |   Michael L. Grantham1 |   
Donald K. Milton1
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2020 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd
R. Lambkin-Williams and AS Gilbert completed this work as employees of hVIVO but left the company in late 2019.  
The peer review history for this article is available at https://publons.com/publo n/10.1111/irv.12790.  
1University of Maryland School of Public 
Health, Maryland Institute for Applied 
Environmental Health, College Park, MD, 
USA
2Division of Epidemiology and Public Heath, 
Health Protection and Influenza Research 
Group, University of Nottingham School of 
Medicine, Nottingham, UK
3hVIVO, London, UK
Correspondence
Paul Jacob Bueno de Mesquita and Donald 
K. Milton, University of Maryland School 
of Public Health, Maryland Institute for 
Applied Environmental Health, College Park, 
MD, 20742, USA.
Emails: jbueno@umd.edu; dmilton@umd.edu
Present address
Robert Lambkin-Williams, virologyconsult.
com
John Forni, Department of Acute and 
Specialty Care, MSD, London, UK
Jovan Pantelic, Center for the Built 
Environment, University of California, 
Berkeley, CA, USA
Michael L. Grantham, Missouri Western 
State University, St. Joseph, MO, USA
Funding information
Centers for Disease Control and Prevention, 
Grant/Award Number: 1U01IP000497 ; 
NIAID Centers of Excellence for Influenza 
Research and Surveillance (CEIRS), Grant/
Award Number: HHSN272201400008C
Abstract
Background: It has long been known that nasal inoculation with influenza A virus 
produces asymptomatic to febrile infections. Uncertainty persists about whether 
these infections are sufficiently similar to natural infections for studying human-to-
human transmission.
Methods: We compared influenza A viral aerosol shedding from volunteers nasally 
inoculated with A/Wisconsin/2005 (H3N2) and college community adults naturally 
infected with influenza A/H3N2 (2012-2013), selected for influenza-like illness with 
objectively measured fever or a positive Quidel QuickVue A&B test. Propensity 
scores were used to control for differences in symptom presentation observed be-
tween experimentally and naturally infected groups.
Results: Eleven (28%) experimental and 71 (86%) natural cases shed into fine particle 
aerosols (P < .001). The geometric mean (geometric standard deviation) for viral posi-
tive fine aerosol samples from experimental and natural cases was 5.1E + 3 (4.72) and 
3.9E + 4 (15.12) RNA copies/half hour, respectively. The 95th percentile shedding 
rate was 2.4 log10 greater for naturally infected cases (1.4E + 07 vs 7.4E + 04). Certain 
influenza-like illness-related symptoms were associated with viral aerosol shedding. 
The almost complete lack of symptom severity distributional overlap between groups 
did not support propensity score–adjusted shedding comparisons.
Conclusions: Due to selection bias, the natural and experimental infections had 
limited symptom severity distributional overlap precluding valid, propensity score–
adjusted comparison. Relative to the symptomatic naturally infected cases, where 
high aerosol shedders were found, experimental cases did not produce high aerosol 
shedders. Studying the frequency of aerosol shedding at the highest observed levels 
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1  | INTRODUC TION
There is uncertainty about the extent to which the site of initial 
exposure within the pulmonary tree influences influenza virus 
infection risk and severity between humans. Experimental nasal 
instillation produces a range of illness from asymptomatic, symp-
tomatic, to febrile. Studies that challenged humans by nasal instil-
lation of virus, and others that challenged with aerosolized virus 
suggest that upper respiratory mucosal exposure, as opposed to 
airborne exposure may result in a higher proportion of milder, 
afebrile illnesses.1-3 Anisotropic infection is defined by Milton 
as infection whereby transmission mode influences illness pre-
sentation,4 and has been used to characterize human influenza.5 
To minimize health risk associated with experimental human in-
fluenza infection, the majority of human challenge models have 
adopted viral inoculation by nasal instillation.6 Associations be-
tween symptomatology and nasal and throat mucosal viral load 
following symptom onset have been reported among volunteers 
receiving intranasal influenza virus challenge and among second-
ary household cases in Hong Kong.7-9 Other analyses of these 
household transmission data did not find temporal associations 
between symptom severity and upper respiratory viral load10; and 
observed upper respiratory mucosal viral loads11,12 or respiratory 
symptoms13 to be poorly predictive of transmission to household 
secondary cases, suggesting that other biomarkers of contagion 
such as exhaled breath aerosols should be explored. The current 
study compares fine aerosol shedding between influenza A/H3 
nasally inoculated and naturally infected cases to test whether 
experimental, nasal-induced infections have similar risk and rate 
of fine aerosol shedding compared with natural cases infected by 
any mode.
2  | METHODS
2.1 | Study design overview
Study design and data collection procedures for the Evaluating 
Modes of Influenza Transmission (EMIT) human challenge-trans-
mission trial14 and the observational study of naturally infected in-
fluenza cases from University of Maryland campus community are 
described elsewhere (SI Appendix S1).15 Half-hour exhaled breath 
specimens are partitioned into fine (≤5 µm) and coarse (>5 µm) aero-
sol fractions during collection by Gesundheit-II bioaerosol sampler 
(G-II).16 Exhaled breath from both studies was evaluated using 
standard CDC qRT-PCR primers and probes at the University of 
Maryland laboratory. Exhaled breath samples were taken on up to 
three consecutive days among naturally infected cases, and on up to 
3 times over 4 days for experimental cases. Nasopharyngeal swabs 
from experimental and natural cases were evaluated with the same 
reagents in separate laboratories. Nasopharyngeal swabs from the 
experimental group were not tested against a plasmid standard for 
experimental cases, limiting comparison of RNA shedding in swabs 
to the cycle threshold (Ct) values. Data were cleaned and analyzed 
in R (v3.5.1 R Development Core Team, Vienna, Austria) and SAS 
Studio (Release 3.7 [Enterprise Edition], v9.4M6).
2.2 | Symptom scores
Symptom scores were measured three times per day for experi-
mental cases and once per day for natural cases during a research 
clinic visit where exhaled breath was collected. Scores taken clos-
est in time to exhaled breath collection were selected for analysis. 
The upper respiratory score was sum of runny nose, stuffy nose, 
sneezing, sore throat, and earache symptom scores (range 0-15). 
The lower respiratory score was the sum of shortness of breath and 
cough scores (range 0-6). The systemic symptom score was the sum 
of malaise, headache, and muscle/join ache scores (range 0-9). The 
tympanic temperature for experimental and oral for naturally in-
fected cases was recorded. Observed cough counts were recorded 
during half-hour breath collections.
2.3 | Adjustment for qRT-PCR detection limit
Tobit regression was used to impute fine aerosol RNA copy num-
ber for qRT-PCR replicates below detection limit where one or 
more replicates for a sample had detectable RNA. Imputation 
of RNA copies was not done for samples without any replicates 
above detection limit, differing from the approach used by Yan and 
colleagues, where there were a minority of fine aerosol samples 
below detection limit (14%).15 It is less reasonable to do the same 
for the experimentally infected population where 72% of the ob-
servations would be imputed. Tobit regression imputed values for 
samples with qRT-PCR detectable RNA in ≥1 replicate. For both 
experimentally and naturally infected populations, Tobit models 
consisted of fixed effects of cough and study day with random 
in natural infections without selection on symptoms or fever would support helpful 
comparisons.
K E Y W O R D S
experimental inoculation, human challenge model, influenza symptomatology, influenza 
transmission, propensity scores, Viral aerosols, viral shedding
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effect of person. Fixed effects for these models were selected 
based on a priori evidence of an association with fine aerosol 
shedding.15
2.4 | Statistics and models to predict shedding
t Tests with equal variances and chi-squared tests were used to com-
pare continuous and categorical demographic and symptom severity 
variables. Fisher's exact tests were used to compare binomial pro-
portions between experimental and natural cases for fine and coarse 
shedding subjects and samples. Welsh's t test for unequal variance 
and the Wilcoxon rank sum test were used to compare geometric 
mean (GM) and median aerosol shedding, respectively. Tests were 
two-tailed. Unadjusted effects on probability of shedding into aero-
sols were estimated with a random effect of person (from gener-
alized linear mixed-effects model) for symptom scores, observed 
cough count, age, sex, and vaccination status. Analysis of aerosol 
shedding risk used all exhaled breath observations. Analysis of shed-
ding quantity used the same predictors refined to the maximum 
shedding day per shedder.
2.5 | Case selection and propensity adjustment
Naturally infected cases were sampled from a symptomatic popula-
tion, selected on the basis of positive QuickVue® rapid test or febrile 
illness >37.8°C (measured at University Health Center where some 
recruitment took place, or upon presentation to research clinic) 
plus cough or sore throat, and included in analysis based on a single 
qRT-PCR–positive nasopharyngeal swab on the day of enrollment. 
Although enrollment of naturally infected cases used a febrile illness 
threshold of >37.8°C, this analysis used the more widely accepted 
threshold of >37.9°C. Experimentally infected cases were selected 
on qRT-PCR detection of virus from nasopharyngeal swabs on at 
least two of six follow-up days, or on one day plus serological evi-
dence of infection. Differences in study design were expected to in-
troduce imbalance in symptom severity distribution between groups 
(SI Appendices S1,S2). If symptoms are associated with aerosol 
shedding in an unselected population, then this would be an impor-
tant variable to control for with the goal of assessing differences in 
shedding between the groups. To minimize the effect of this bias, we 
attempted to balance covariate distributions between populations 
with propensity score models (SI Appendix S3).
2.6 | Data availability statement
The study data for experimental volunteers are available in the 
public repository at Nottingham University at https://rdmc.notti 
ngham.ac.uk/handl e/inter nal/8311 (DOI: http://doi.org/10.17639 /
nott.7051). The study data for natural infections are available upon 
request. All analysis scripts and readme files required to reproduce 
analyses are available at https://gitlab.com/jacob bueno /natur al_vs_
artif icial_infec tion
3  | RESULTS
For 39 experimental and 83 naturally infected influenza A H3 cases, 
there were 84 and 146 exhaled breath collection instances, respec-
tively. Of the 39 confirmed experimental cases, 36 were qRT-PCR 
positive two or more days, 31 of whom also had serological evidence 
of infection; three were qRT-PCR positive on one day only and had 
serological evidence of infection. A total of 52 challenge study vol-
unteers were inoculated, giving an infection rate of 75%, based on 
the current case infection definition.
Both study populations of young adults were generally healthy. 
The experimental group was on average 10 years older than the nat-
urally infected. Experimental cases were more likely to be male, while 
naturally infected cases were balanced by sex (Table 1). Experimental 
cases had illness mostly characterized by upper respiratory symp-
toms or were asymptomatic (12.8%) (Table 1). There were small 
peaks in upper respiratory, lower respiratory, systemic, and cough 
scores, and cough counts on day 3 post-inoculation. Naturally in-
fected cases had more severe symptoms scores and greater cough 
counts, with symptom scores peaking on day 1 post-symptom onset 
and aligning with day 3 post-inoculation (Figure S2).
The risk of shedding virus into coarse and fine aerosols for exper-
imentally infected was 6/39 (15%) and 11/39 (28%), and for naturally 
infected 45/83 (54%) and 71/83 (86%) (Table 2). Median coarse and 
fine aerosol shedding quantity between the groups was significantly 
higher for natural cases in both fine (P < .001) and coarse (P < .001) 
aerosol fractions. Peak aerosol shedding was observed on day 3 
post-inoculation and day 1 post-symptom onset for experimental 
and natural cases, respectively, matching peak symptom score day 
alignment (Figure 1). No virus was detected in fine aerosols on day 1 
post-inoculation in experimental cases. On the day of peak aerosol 
shedding, median symptom scores for experimental infection were 
upper respiratory 4 (IQR 2, 5), lower respiratory 0 (0, 1), systemic 1 
(0, 2), cough 0 (0, 1), and cough count 0 (0, 6) and for natural infec-
tions 7 (5, 9), 3 (2, 4), 6 (4, 8), 2 (2, 3), and 22 (8, 40), respectively.
When using all the detectable qRT-PCR nasopharyngeal swab 
samples from days 1-6 post-inoculation (N = 179) and 1-3 post-symp-
tom onset (N = 143), Ct values were notably lower for natural com-
pared with experimental cases (Figure S3). The lowest Ct values 
were seen on day 1 post-symptom onset in naturally infected cases 
and day 3 post-inoculation; subsequent days showed a faster rise in 
Ct for experimental compared with natural cases.
Restricted to maximum shedding observations by aerosol frac-
tion, the GM (geometric standard deviation, GSD) for coarse and 
fine aerosols was 2.7E + 3 (3.3) and 5.1E + 3 (4.7) for experimen-
tally, and 2.1E + 4 (16.5) and 5.1E + 4 (17.0) for naturally infected 
cases (Table 2, Figure S4). Descriptive statistics for covariates during 
maximum fine aerosol shedding observation days (Table S3) are sim-
ilar to those derived from all observation days. Upper respiratory 
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symptoms score distributions overlapped the most between groups, 
while differences in the distributions of lower respiratory, systemic, 
and cough symptoms scores, and cough count were more pro-
nounced (Figure 2).
For the experimental cases, unadjusted upper and lower respi-
ratory scores, cough symptoms, and cough count were positively 
associated with fine aerosol shedding detection (Table 3). For nat-
urally infected cases, unadjusted lower respiratory symptom scores 
and cough symptoms were positively associated with fine aerosol 
shedding risk. Study day was negatively associated with aerosol 
shedding in naturally infected cases. Nasopharyngeal swab qRT-PCR 
cycle threshold (Ct) value had a negative association with aerosol 
shedding risk for both groups. There were no significant predictors 
of aerosol shedding rate among experimental or natural cases. Of 
the experimentally infected, only males shed detectable virus into 
aerosols. Of the naturally infected, 57/69 (82.6%) unvaccinated and 
14/14 (100%) vaccinated with the current influenza season vaccine 
shed into aerosols above detection limit, while 61/73 with and 10/10 
without vaccination for the current and previous influenza seasonal 
vaccine shed virus into aerosols at measurable levels.
After extensive testing, the best propensity score model (co-
variates: fever >37.8°C, body temperature, and upper respiratory 
symptom score) and adjustment by inverse probability weighting for 
average treatment effect (ATE) minimized the standardized differ-
ences between the groups with mean absolute value standardized 
difference of 91 (Table S5). After ATE adjustment, balance improved 
for some covariates, however not to the point where they could be 
considered similar (Figure 3, Table S5). Although it is advisable that 
absolute standardized differences for covariates not exceed 10% be-
tween comparison groups, and variance ratios approach one (range 
0.5-2),17 the best model with weighted adjustment had absolute 
standardized differences ranging 7.3%-169.1% and variance ratios up 
to 48.5. The substantial differences between covariate distributions 
did not support the use of propensity score–adjusted approaches for 
making further comparisons between these populations.
4  | DISCUSSION
We compared aerosol RNA shedding in influenza A (H3) cases in-
fected naturally and by nasal instillation under experimental condi-
tions. Previously, we cultured influenza virus from exhaled breath 
showing that quantitative culture correlates with RNA copy detec-
tion (r = .34, P < .0001).15 A minority of experimental cases shed 
virus into aerosols (28%). A far greater proportion of the naturally 
infected study population shed into aerosols (86%). Among the ex-
perimentally infected with detectable viral aerosols, the fine RNA 
copy GM was within log10 that for naturally infected cases. A more 
substantial difference in fine aerosol shedding rate was observed at 
the level of the overall distribution, with increases in median and 
upper percentiles for naturally infected cases (Figure S4). Compared 
with naturally infected cases at the 95th percentile of fine aerosol 
shedding, experimentally infected cases shed nearly 2.5 log10 fewer 
RNA copies. Given the selection of naturally infected cases on ILI 
symptoms and/or a positive rapid antigen test, and an observed 
TA B L E  1   Demographics and symptomatology of influenza A 
Cases
Experimental Natural
P 
value
N-Participants 39 83
Age 29.9 (7.0) 22.3 (7.6) 6E-7
Range 20.0-45.0 15.0-63.0
N-Female (%) 11 (28.2) 47 (56.6) .003
N-asymptomatic (%)a  5 (12.8) 0 (0.0) .003
N-with fever > 37.9°C 
(%)
6 (15.4) 36 (43.4) .002
N-with flu vaccine in 
current yr (%)
0 (0) 14 (16.8) E-4
N-with flu vaccine in 
current and previous 
yr (%)
0 (0) 10 (12.0) .001
N-Breath collection 
visits
84 146
Temperature in C 36.6 (0.6) 37.3 (0.6) 4E-16
N-Missing 
observations
2 1
Range 35.3-38.4 36.3-39.7
Upper respiratory 
symptom score
1.4 (1.9) 7.0 (3.0) E-22
Range 0.0-6.0 0.0-15.0
Lower respiratory 
symptom score
0.2 (0.4) 3.2 (1.5) E-22
Range 0.0-1.0 0.0-6.0
Systemic symptom 
score
0.7 (1.2) 5.4 (2.4) E-22
Range 0.0-5.0 0.0-9.0
Total symptom score 2.2 (2.9) 15.5 (5.5) E-22
Range 0.0-11.0 4.0-29.0
Cough symptom scoreb  0.2 (0.4) 2.2 (0.8) E-22
Range 0.0-1.0 0.0-3.0
Cough countc  1.7 (4.8) 26.7 (32.5) 3E-11
Range 0.0-35.0 0.0-265.0
Nasopharyngeal swab 
Ct valued 
29.9 (6.9) 23.1 (6.1) E-7
N-Missing 
observations
2 0
Range 17.0-40.0 13.1-40.0
Note: Mean (SD) unless indicated (N = number). Symptom scores, body 
temperature, and observed cough counts are reported per breath 
collection visit, with multiple visits per person.
aNever fever >37.9°C or any self-reported symptom. 
bCough symptom score is part of composite lower respiratory score. 
cCough counts after imputation for five experimental and three natural 
case observations. 
dSwabs with no detection were coded as having Ct value = 40. 
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relationship between symptoms and shedding (Table 3), it is possi-
ble that aerosol shedding observed for the naturally infected study 
populations overestimates what might be expected for a sample rep-
resentative of all naturally acquired infections.
Peak RNA copies shed into aerosols on day 3 post-nasal inocula-
tion was one day later than that observed in upper respiratory mu-
cosa in previous challenge studies,7 yet consistent with the 1-2 day 
post-symptom onset nose and throat swab viral load peak from 
household contact surveillance studies.8 There are no available data 
with which to compare the current study's aerosol shedding. If we 
take previous estimates of ~ 1-2 days as the influenza A incubation 
period, plus about day 1 post-symptom onset to reach peak aerosol 
shedding in the naturally infected population, then we would expect 
peak aerosol shedding on ~2-3 days following exposure to virus. 
This is consistent with the peak in aerosol shedding in the experi-
mentally infected cases at day 3 post-inoculation, suggesting that 
the progression of infection from exposure to replication is consis-
tent with the natural infection group and with other studies. The 
significant decrease in aerosol shedding by day post-onset (Table 3) 
among the naturally infected, but not the experimental cases, could 
be related to failure to detect a clear trend against a background 
of very much lower overall aerosol shedding for the experimental 
TA B L E  2   Viral shedding into exhaled breath aerosols for experimental and natural infections
All exhaled breath observations
Experimental Natural
P value(39 subjects; 84 GII obs.) (83 subjects; 146 GII obs.)
Coarse Fine Coarse Fine Coarse Fine
No. of positive subjects 
(%)
6 (15) 11 (28) 45 (54) 71 (86) 6E-5 7E-10
No. of positive samples 
(%)
6 (7) 14 (17) 66 (45) 111 (76) 2E-10 7E-19
RNA copy GM (GSD)a  2.7E + 3 (3.3) 5.1E + 3 (4.7) 1.8E + 4 (13.9) 3.9E + 4 (15.1) .002
(t = −3.9, df = 12.9)
.005
(t = −3.3, df = 16.1)
RNA copies by percentile
25th ND ND ND 1.3E + 3
Median ND ND ND 7.9E + 3 E-9b  3E-18b 
75th ND ND 6.6E + 3 7.6E + 4
90th ND 2.0E + 3 7.4E + 4 1.1E + 6
95th 1.3E + 3 6.4E + 3 8.5E + 5 6.5E + 6
Maximum 2.8E + 4 8.0E + 4 4.3E + 8 4.4E + 7
Maximum shedding exhaled breath observations
Experimental Natural
P value(11 subjects; 11 GII obs.) (71 subjects; 71 GII obs.)
Coarse Fine Coarse Fine Coarse Fine
RNA copy GM (GSD) 2.7E + 3 (3.3) 5.0E + 3 (5.8) 2.1E + 4 (16.5) 5.1E + 4 (17.0) 0.0002
(t = −4.2, df = 35.9)
0.003
(t = −3.5, df = 14.7)
RNA copies by percentile
25th ND 1.5E + 3 ND 5.8E + 3
Median ND 2.0E + 3 1.7E + 3 2.2E + 4 .02 .003
75th ND 3.5E + 4 1.0E + 4 3.9E + 5
90th 1.4E + 3 6.7E + 4 4.2E + 5 6.3E + 6
95th 2.2E + 3 7.4E + 4 9.8E + 5 1.4E + 7
Maximum 2.8E + 4 8.0E + 4 4.3E + 8 4.4E + 7
Note: Samples collected days 1-4 post-inoculation in the experimentally infected and days 1-3 post-symptom onset in the naturally infected. 
Shedding per half-hour sample.
Abbreviations: df, degrees of freedom; GM, geometric mean; GSD, geometric standard deviation; ND, not detected; t, t test value.
aOnly samples with detectable RNA (at least one positive replicate) contributed to GM and GSD (fine aerosol: N = 14 experimental, N = 111 natural; 
coarse aerosol: N = 6 experimental, N = 66 natural). 
bWhen restricted to samples with detectable RNA, Wilcoxon rank sum tests gave P = .03 (coarse) and P = .003 (fine). 
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group. The temporal decline observed for naturally infected cases 
along with previous reports of less temporal decline in viral load 
from nasopharyngeal swabs compared with fine aerosols following 
day 1 post-symptom onset,15 and a tendency for nasal viral load to 
overestimate transmission risk after day 3 post-symptom onset,12 
suggests aerosol shedding may better fit epidemiologically observed 
transmission dynamics over time in the household setting.
Unadjusted lower respiratory and cough symptom scores were 
associated with viral aerosol detection in both groups with a clear 
dose-response relationship in cough score for the naturally infected 
cases, supporting the notion of a symptomatology-shedding rela-
tionship for aerosols. Peak symptom scores and aerosol shedding 
coincided, consistent with the temporal dynamics of other stud-
ies.7-9 However, regression analyses that restricted observations 
to maximum fine aerosol samples found mostly weak and unstable 
effects of symptoms on shedding rate (Table S4). These data should 
be interpreted with caution given limited heterogeneity in symptom 
severity, with milder illness characteristic of the experimental cases 
and more moderate to severe illness characteristic of the naturally 
infected cases. It may be for this reason that other studies have 
F I G U R E  1   Aerosol shedding over 
time. Includes all observations (N = 84 
experimental and N = 146 natural). 
Detectable aerosol shedding in log10 
aerosol copies, with boxes showing the 
interquartile range (IQR) with a band 
to indicate the median, and whiskers 
extending to the highest and lowest data 
points within 1.5 IQR
F I G U R E  2   Comparison of self-reported symptoms and observed coughs from maximum fine aerosol shedding days (N = 11 experimental 
(blue), N = 71 natural (red) observations). Cough counts with boxes showing the inner-quartile range (IQR) with a band to indicate the 
median, and whiskers extending to the highest and lowest data points within 1.5 IQR
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reported mixed results with respect to associations between symp-
tomatology and nose/throat viral load.9,10 Nevertheless, that fever 
was observed in 43% of naturally infected and 15% of experimen-
tally infected cases and may indicate that febrile periods of illness 
are associated with increased infectivity risk. Studying cases with a 
broader range of symptom severity could provide additional insight 
into symptom-shedding relationships with useful implications for 
identifying contagious symptom profiles.
There is growing evidence that airborne transmission plays an 
important role in the spread of influenza.5,14,18,19 Humans exper-
imentally challenged to influenza virus by airborne particles had 
a 50% risk of infection to a 0.6-3.5 TCID50 dose and exhibited in-
creased propensity for moderate to severe illness with fever and 
cough compared with others experimentally challenged by nasal 
droplets.1,2 The term anisotropic has been used to describe such in-
fections where inoculation mode determines illness presentation.4,5 
A population of cases with naturally acquired infections may be ex-
pected to demonstrate a higher proportion of moderate-severe in-
fluenza-like illness compared with a population of cases exclusively 
infected by exposure to the nasal mucosa. Compared with other 
symptoms, systemic scores declined more rapidly following day 1 
post-symptom onset for natural cases, consistent with other find-
ings8 and suggestive of the immune system clearing systemic infec-
tion. These findings may hint that natural cases may be more likely 
to result in lung and systemic infection initiated by an airborne dose, 
whereas experimentally infected cases with only nasal mucosal ex-
posure were more likely to have few if any systemic symptoms and 
illness more localized to the upper respiratory tract.
Given the selection bias and the contrasted symptom profiles in 
two populations and observed associations between symptoms and 
shedding, we attempted to adjust for the effect of symptoms to un-
derstand the direct effect of experimental vs natural infection on the 
viral load in fine particle aerosols (Figure 3, Figure S1 of SI Appendix 
S2). Ultimately, propensity score modeling failed to balance the dis-
tribution of covariates between groups and we concluded that the 
groups were simply too different to achieve an unbiased estimate of 
the main effect of group membership (experimental vs natural) on 
shedding strength. Assuming minimal contribution of potential con-
founders on the pathway between mode of inoculation and study 
population membership (ie, age, sex, host immunity, virus pathoge-
nicity, dose), we cannot conclude that the unadjusted differences in 
symptomatology and shedding are a result of mode of inoculation, 
or simply the result of the differences inherent in recruitment and 
enrollment procedures and other potentially unobserved confound-
ers in the absence of a randomized controlled design. Because it is 
unclear that any subsets of cases from each group could be selected 
to make valid comparisons, we decided to present crude population 
differences with respect to viral aerosol shedding in Tables 2, 3, and 
Table S4, and include everyone meeting case definition (including 
the 5/39 asymptomatic volunteer cases). We emphasize that all 
cases had qRT-PCR evidence of infection (Methods).
Identifying naturally infected reference groups that represent the 
true distribution of symptom severity presents a challenge. Although 
a substantial proportion of cases are asymptomatic, symptomatic 
community cases are more prone for inclusion in epidemiologic 
studies upon seeking medical attention.20 Multi-year sero-surveil-
lance of large cohorts in the UK shows influenza infections pre-
sented asymptomatically at a rate of 77 per 100 person-seasons.21 
A meta-analysis of longitudinal studies using serological evidence of 
infection and controlling for background illness reported a 65%-85% 
TA B L E  3   Unadjusted odds ratios on shedding detectable virus 
into fine aerosols
Predictor
Experimental
OR (95% CI)
Natural
OR (95% CI)
Age 1.03 (0.94-1.14) 0.95 (0.70-1.27)
Sexa  – 2.61 (0.65-10.43)
Ever fever > 37.9°C 3.12 (0.52-18.67) 0.73 (0.21-2.49)
Study dayb 
Day 1 – 1.00 (REF)
Day 2 1.00 (REF) 0.25 (0.06-1.03)
Day 3 50.89 (0.07-30,636) 0.17 (0.04-0.73)
Day 4 0 (0-7.51) –
Body 
temperature (oC)
4.77 (0.94-24.17) 1.88 (0.87-4.06)
Upper respiratory 
score
2.24 (1.07-4.69) 1.07 (0.93-1.22)
Lower respiratory 
score
6.49 (1.14-37.09) 1.35 (1.04-1.76)
Systemic symptom 
score
1.73 (0.94-3.16) 1.15 (0.97-1.36)
Total symptom score 1.64 (1.09-2.47) 1.07 (0.99-1.15)
Cough symptom scorec 
No symptom 1.00 (REF) 1.00 (REF)
Mild 7.49 (1.28-43.91) 8.5 (0.81-88.85)
Moderate – 12.92 
(1.32-126.08)
Severe – 20.4 
(2.06-202.21)
Cough count 1.29 (1.02-1.62) 1.92 (1-3.65)
Nasopharyngeal 
swab Ct
0.74 (0.6-0.92) 0.98 (0.91-1.05)
Note: Symptom ORs (odds ratios) used data from N = 84 experimental 
and N = 146 natural observations (all exhaled breath observations and 
accompanying symptom data from 39 experimental and 83 natural 
cases). ORs for age, sex, ever fever > 37.9°C, used data from N = 39 
experimental, and N = 83 natural cases. Effect of a single unit increase 
in age, body temperature, symptoms scores, and nasopharyngeal swab 
Ct; effect of interquartile range (IQR) increase in cough count, ever 
fever > 37.9°C vs afebrile, male vs female. Bold: significant at P < .05. 
Random effect of person.
aOnly males shed into aerosols in the experimental group. 
bDay post-nasal inoculation for experimental (range 1-4); day post-
symptom onset for natural (range 1-3). No fine aerosol shedding was 
observed on day 1 post-inoculation. 
cModerate or severe cough was never observed in the experimental 
group. 
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asymptomatic fraction.22 It is possible that the experimentally in-
fected cases are not substantially different in symptomatology from 
a representative sample of all influenza infections. Accessing a rep-
resentative sample might be achieved through intensive household 
or dormitory surveillance of contacts of known cases.
The infectious dose for airborne influenza and the infectious 
potential of cases infected by various modes are largely unknown. 
If the typical fine aerosol shedding rate from influenza cases is im-
portant for driving airborne transmission, then our findings would 
indicate that nasal mucosal exposure in the experimental challenge 
model produces cases with airborne infectious potential similar to 
symptomatic cases infected naturally by contact, large droplets, or 
fine aerosols. If above-average shedders are important for driving 
airborne transmission (ie, superspreader hypothesis), then infections 
acquired through nasal mucosa may not pose as much airborne in-
fectious potential. If we assume hypothetically that the symptom-
atic naturally infected cases drawn from the University of Maryland 
campus community represent the upper 1% of symptom severity 
and shedding strength in a broader population, and if we also as-
sume that the experimental cases are representative of total com-
munity infections, the chances of an experimental case reaching 
the level of fine aerosol shedding observed in the naturally infected 
group would be 0.39% (1% of 39 experimental cases). If shedders in 
the upper percentiles of shedding rate are responsible for driving 
transmission, then it would take many more experimental cases to 
adequately simulate transmission events in a human transmission 
challenge trial model. This introduces logistical challenges and mo-
tivates work to identify, among naturally infected shedders, charac-
teristics predictive of aerosols (and mucosal) shedding. In particular, 
response to infection by different modes may vary between children 
and adults, with implications for subsequent infectivity and popula-
tion epidemiology.10,13,23,24 Clinical detection of infections that may 
be associated with disease severity and potential for self-isolation or 
other behaviors that could modify contagiousness should be consid-
ered in population-level transmission risk assessment.
Given bias introduced by selection of natural infections on symp-
toms plus fever or rapid antigen test, the observed correlations of 
symptoms and fever with viral shedding into aerosols, and a small 
N with minimal covariable distributional overlap precluding appro-
priate adjustment, we conclude that the naturally infected pop-
ulation is too different from the experimentally infected cases to 
make valid comparisons. Our observations show that the 52 nasally 
inoculated experimental cases produced viral aerosol shedders less 
frequently than the 83 symptomatic naturally infected population. 
When they did shed detectable virus into aerosols, the experimental 
cases did so at substantially lower quantities than the symptomatic 
naturally infected group. This difference in aerosol shedding was 
most pronounced when comparing the highest percentiles of aero-
sol shedding for each group. The probability and quantity of aero-
sol shedding in unselected natural infection is unknown. Therefore, 
these findings encourage efforts to evaluate shedding from infec-
tions observed during contact surveillance without selection based 
on symptoms or fever.
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